LA
GILD icon

Lynch & Associates’s Gilead Sciences GILD Stock Holding History

Lynch & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-16,865
Closed -$1.3M – 102
2020
Q2 		$1.3M Buy
16,865
+295
+2% +$22.6K 0.42% 53
2020
Q1 		$1.24M Buy
16,570
+1,335
+9% +$92.2K 0.46% 50
2019
Q4 		$990K Buy
15,235
+625
+4% +$40.7K 0.28% 60
2019
Q3 		$926K Sell
14,610
-1,200
-8% -$78.4K 0.28% 57
2019
Q2 		$1.07M Sell
15,810
-1,200
-7% -$78.9K 0.35% 56
2019
Q1 		$1.11M Sell
17,010
-200
-1% -$13.3K 0.37% 54
2018
Q4 		$1.08M Sell
17,210
-1,925
-10% -$135K 0.4% 52
2018
Q3 		$1.48M Buy
19,135
+594
+3% +$44.9K 0.5% 49
2018
Q2 		$1.31M Buy
18,541
+1,431
+8% +$101K 0.48% 51
2018
Q1 		$1.29M Buy
17,110
+1,235
+8% +$98.2K 0.49% 50
2017
Q4 		$1.14M Buy
15,875
+1,450
+10% +$110K 0.43% 53
2017
Q3 		$1.17M Buy
+14,425
New +$1.1M 0.46% 51

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Lynch & Associates's GILD Position: Q3 2020 in Review

Lynch & Associates sold out of Gilead Sciences (GILD) in Q3 2020, closing a stake of 16,865 shares — an estimated $1.3M sold.

Lynch & Associates first reported a position in GILD in Q3 2017 and held it in 12 quarters. The position peaked at $1.48M in Q3 2018. 1,538 funds tracked by Wall St. Rank hold GILD as of Q3 2020.

  • Lynch & Associates reported no remaining Gilead Sciences position as of Q3 2020 after selling out during the quarter.
  • Lynch & Associates sold 16,865 Gilead Sciences shares in Q3 2020, an estimated $1.3M.
  • Lynch & Associates first reported a position in Gilead Sciences in Q3 2017 and held it in 12 quarters.
  • Lynch & Associates's Gilead Sciences position peaked at $1.48M in Q3 2018.
  • 1,538 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2020.

Based on Lynch & Associates's 13F filing for Q3 2020, filed 21 Oct 2020.